Example of Drug and Therapeutics Bulletin format
Recent searches

Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format Example of Drug and Therapeutics Bulletin format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access ISSN: 126543 e-ISSN: 17555248

Drug and Therapeutics Bulletin — Template for authors

Categories Rank Trend in last 3 yrs
Pharmacology (medical) #205 of 246 down down by 10 ranks
journal-quality-icon Journal quality:
Low
calendar-icon Last 4 years overview: 214 Published Papers | 86 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 04/07/2020
Insights & related journals
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Journal Performance & Insights

  • CiteRatio
  • SJR
  • SNIP

CiteRatio is a measure of average citations received per peer-reviewed paper published in the journal.

0.4

33% from 2019

CiteRatio for Drug and Therapeutics Bulletin from 2016 - 2020
Year Value
2020 0.4
2019 0.3
2018 0.3
2017 0.3
2016 0.3
graph view Graph view
table view Table view

insights Insights

  • CiteRatio of this journal has increased by 33% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR) measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

0.147

11% from 2019

SJR for Drug and Therapeutics Bulletin from 2016 - 2020
Year Value
2020 0.147
2019 0.132
2018 0.124
2017 0.117
2016 0.119
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has increased by 11% in last years.
  • This journal’s SJR is in the top 10 percentile category.

Source Normalized Impact per Paper (SNIP) measures actual citations received relative to citations expected for the journal's category.

0.263

116% from 2019

SNIP for Drug and Therapeutics Bulletin from 2016 - 2020
Year Value
2020 0.263
2019 0.122
2018 0.04
2017 0.022
2016 0.032
graph view Graph view
table view Table view

insights Insights

  • SNIP of this journal has increased by 116% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Related Journals

open access Open Access ISSN: 14737175 e-ISSN: 17448360

Taylor and Francis

CiteRatio: 6.4 | SJR: 1.187 | SNIP: 1.192
open access Open Access ISSN: 2698811 e-ISSN: 14617285

SAGE

CiteRatio: 6.1 | SJR: 1.333 | SNIP: 1.061
open access Open Access ISSN: 17539447 e-ISSN: 17539455

SAGE

CiteRatio: 4.8 | SJR: 1.164 | SNIP: 1.22
open access Open Access ISSN: 20420986 e-ISSN: 20420994

SAGE

CiteRatio: 6.3 | SJR: 1.196 | SNIP: 1.603
Drug and Therapeutics Bulletin

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

BMJ Publishing Group

Drug and Therapeutics Bulletin

For nearly 50 years, DTB has provided rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals. DTB was started in 1962. From the outset, it has pro...... Read More

Medicine

i
Last updated on
04 Jul 2020
i
ISSN
0012-6543
i
Impact Factor
Low - 0.254
i
Open Access
No
i
Sherpa RoMEO Archiving Policy
Green faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
unsrt
i
Citation Type
Numbered
[25]
i
Bibliography Example
C. W. J. Beenakker. Specular andreev reflection in graphene. Phys. Rev. Lett., 97(6):067007, 2006.

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.1136/DTB.2019.000008
How to communicate evidence to patients.
Alexandra L. J. Freeman1

Abstract:

All medical treatments have potential harms as well as benefits, and it is vital that everyone has a good understanding of what these might be, how dramatic they might be and how likely. In fact, in the UK, the Montgomery judgement in the supreme court in 2015 (see Box 1) has made it a legal necessity for patients to be given... All medical treatments have potential harms as well as benefits, and it is vital that everyone has a good understanding of what these might be, how dramatic they might be and how likely. In fact, in the UK, the Montgomery judgement in the supreme court in 2015 (see Box 1) has made it a legal necessity for patients to be given comprehensible, personally relevant information about all reasonable treatment options, including none.1 So, how should we ensure good, clear communication of relevant evidence? Box 1. ### The Montgomery judgement In 1999, Nadine Montgomery was preparing for the birth of her son Sam. She was of small stature, with diabetes, and was concerned about being able to give birth naturally. Unfortunately, difficulties did arise during birth, and Sam suffered brain damage as a result. Her obstetrician had not discussed the risk of this particular complication occurring, deeming it best Nadine attempted a vaginal birth. On appeal at the supreme court, Nadine Montgomery won her case. This laid down a new legal basis for informed consent, in line with the General Medical Council guidelines;1 > “The doctor is therefore under a duty to take reasonable care to ensure that the patient is aware of any material risks involved in any recommended treatment, and of any reasonable alternative or variant treatments.” > > “The test of materiality is whether, in the circumstances of the particular case, a reasonable person in the patient's position would be likely to attach significance to the risk, or the doctor is or should reasonably be aware that the particular patient would be likely to attach significance to it. ” > > “The assessment of whether a risk is material cannot be reduced to percentages. The significance of a given risk is likely to reflect a variety of factors besides its magnitude” > > “The doctor’s advisory role involves dialogue, … read more read less

Topics:

Reasonable person (53%)53% related to the paper
View PDF
14 Citations
Journal Article DOI: 10.1097/00012995-198002000-00001
Can adverse drug reactions be prevented

Topics:

Dose dumping (72%)72% related to the paper
13 Citations
Journal Article DOI: 10.1136/DTB.2018.000035
Central sensitisation: another label or useful diagnosis?

Abstract:

### Key learning points Chronic pain affects up to 30% of the Western population with a prevalence higher than any other chronic disease.1 Chronic pain is often of a non-specific nature, implying that there is no tissue damage, or that tissue damage is not severe enough to explain the pain experience and/or related symptoms.... ### Key learning points Chronic pain affects up to 30% of the Western population with a prevalence higher than any other chronic disease.1 Chronic pain is often of a non-specific nature, implying that there is no tissue damage, or that tissue damage is not severe enough to explain the pain experience and/or related symptoms. This non-specific nature accounts for non-cancer pain as well as post-cancer pain (ie, pain in cancer survivors). Chronic pain has a significant personal and socioeconomic impact: among long-term conditions, it is responsible for the highest number of years lived with disability and is the most expensive cause of work-related disability.2–4 Chronic pain also decreases life expectancy, in part due to excess deaths from cancer and cardiovascular disease.5–7 Over the past decades, neuroscience has advanced our understanding about pain, including the role of CNS sensitisation—more briefly termed central sensitisation (CS). The original definition for CS—‘an amplification of neural signaling within the CNS that elicits pain hypersensitivity’—originated from laboratory research, but nowadays the chronic pain management field has more or less … read more read less

Topics:

Chronic pain (74%)74% related to the paper, Population (51%)51% related to the paper
View PDF
13 Citations
Journal Article DOI: 10.1136/DTB.2004.4211
Medical aspects of drug use in the gym

Abstract:

Use of performance-enhancing drugs by athletes and bodybuilders appears to be common in the UK.1–3 Although there are no comprehensive national figures, there is evidence that such drugs are also widely used in sections of the general and gym-using populations, in the expectation of physical and cosmetic benefits.1,4 Use of p... Use of performance-enhancing drugs by athletes and bodybuilders appears to be common in the UK.1–3 Although there are no comprehensive national figures, there is evidence that such drugs are also widely used in sections of the general and gym-using populations, in the expectation of physical and cosmetic benefits.1,4 Use of performance-enhancing drugs often takes place with little knowledge or acceptance of potential harmful effects, and clinicians in many settings may see patients who are experiencing problems related to such (usually covert) use. Here we consider medical aspects of performance-enhancing drugs. read more read less

Topics:

Anabolic Agents (55%)55% related to the paper
12 Citations
Journal Article DOI: 10.1136/DTB.2018.000028
Overview of Gilbert's syndrome.
D King1, Matthew J. Armstrong1

Abstract:

### Key learning points Gilbert’s syndrome (GS) is a benign hereditary disorder of bilirubin conjugation resulting in an isolated, elevated blood level of unconjugated bilirubin.1 GS affects 2%–10% of the Caucasian population in the Western world.2,3 The inheritance pattern for GS is commonly autosomal recessive, but can be ... ### Key learning points Gilbert’s syndrome (GS) is a benign hereditary disorder of bilirubin conjugation resulting in an isolated, elevated blood level of unconjugated bilirubin.1 GS affects 2%–10% of the Caucasian population in the Western world.2,3 The inheritance pattern for GS is commonly autosomal recessive, but can be dominant as well; however, genetic counselling is not necessary as there is no impact on life expectancy. For the patient, however, the condition may be an initial cause for concern as they commonly present with painless, non-pruritic jaundice or an incidental finding of hyperbilirubinaemia on routine blood testing. Episodes of jaundice may be exacerbated by heavy physical exertion, fasting, sleep deprivation, alcohol, dehydration, surgery and concurrent illness. Patients will have normal liver enzymes, normal liver synthetic function (clotting, albumin) and a negative haemolysis screen. GS is a diagnosis of exclusion. The primary care practitioners’ main aim is to confirm the diagnosis, reassure the patient and clarify any concerns related to the condition. GS does not require secondary care referral and is largely asymptomatic. Observational studies highlight that the antioxidant effect of unconjugated bilirubin may confer a survival benefit to patients,4,5 and indeed, the greatest risk to those with the condition is in pursuit of an alternative diagnosis. Patients should … read more read less

Topics:

Gilbert's syndrome (57%)57% related to the paper, Jaundice (55%)55% related to the paper, Haemolysis (52%)52% related to the paper, Diagnosis of exclusion (52%)52% related to the paper
11 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Drug and Therapeutics Bulletin.

It automatically formats your research paper to BMJ Publishing Group formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Drug and Therapeutics Bulletin format uses unsrt citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

Absolutely not! With our tool, you can freely write without having to focus on LaTeX. You can write your entire paper as per the Drug and Therapeutics Bulletin guidelines and autoformat it.

Yes. The template is fully compliant as per the guidelines of this journal. Our experts at SciSpace ensure that. Also, if there's any update in the journal format guidelines, we take care of it and include that in our algorithm.

Sure. We support all the top citation styles like APA style, MLA style, Vancouver style, Harvard style, Chicago style, etc. For example, in case of this journal, when you write your paper and hit autoformat, it will automatically update your article as per the Drug and Therapeutics Bulletin citation style.

You can avail our Free Trial for 7 days. I'm sure you'll find our features very helpful. Plus, it's quite inexpensive.

Yup. You can choose the right template, copy-paste the contents from the word doc and click on auto-format. You'll have a publish-ready paper that you can download at the end.

A matter of seconds. Besides that, our intuitive editor saves a load of your time in writing and formating your manuscript.

One little Google search can get you the Word template for any journal. However, why do you need a Word template when you can write your entire manuscript on SciSpace, autoformat it as per Drug and Therapeutics Bulletin's guidelines and download the same in Word, PDF and LaTeX formats? Try us out!.

Absolutely! You can do it using our intuitive editor. It's very easy. If you need help, you can always contact our support team.

SciSpace is an online tool for now. We'll soon release a desktop version. You can also request (or upvote) any feature that you think might be helpful for you and the research community in the feature request section once you sign-up with us.

Sure. You can request any template and we'll have it up and running within a matter of 3 working days. You can find the request box in the Journal Gallery on the right sidebar under the heading, "Couldn't find the format you were looking for?".

After you have written and autoformatted your paper, you can download it in multiple formats, viz., PDF, Docx and LaTeX.

To be honest, the answer is NO. The impact factor is one of the many elements that determine the quality of a journal. Few of those factors the review board, rejection rates, frequency of inclusion in indexes, Eigenfactor, etc. You must assess all the factors and then take the final call.

SHERPA/RoMEO Database

We have extracted this data from Sherpa Romeo to help our researchers understand the access level of this journal. The following table indicates the level of access a journal has as per Sherpa Romeo Archiving Policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

The 5 most common citation types in order of usage are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

Our journal submission experts are skilled in submitting papers to various international journals.

After uploading your paper on SciSpace, you would see a button to request a journal submission service for Drug and Therapeutics Bulletin.

Each submission service is completed within 4 - 5 working days.

Yes. SciSpace provides this functionality.

After signing up, you would need to import your existing references from Word or .bib file.

SciSpace would allow download of your references in Drug and Therapeutics Bulletin Endnote style, according to bmj-publishing-group guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Drug and Therapeutics Bulletin formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template